A. Rodríguez

发表

Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma.

H. Kantarjian, F. Cabanillas, A. Younes, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma.

P. Mclaughlin, J. Cox, F. Cabanillas, 1998, Blood.

High-dose chemotherapy for relapsed and refractory diffuse large B-cell lymphoma: mediastinal localization predicts for a favorable outcome.

B. Andersson, U. Popat, M. de Lima, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sequential therapy in advanced non-small-cell lung cancer with weekly paclitaxel followed by cisplatin-gemcitabine-vinorelbine. A phase II study.

E. Espinosa, J. Feliu, J. Chacón, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study

D. Amadori, D. Dearnaley, M. Climent, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

LENALIDOMIDE AND OBINUTUZUMAB WITH CHOP FOR NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA: PHASE I/II RESULTS

Y. Oki, K. Young, L. Fayad, 2017 .

Clinical value of CEA and CA125 regarding relapse and metastasis in resectable non-small cell lung cancer.

C. Coca, A. Martín Duce, M. Galván, 2003, Anticancer research.

Hodgkin's disease with a mediastinal mass greater than 10 cm: results of four different treatment approaches.

F. Cabanillas, J. Cox, P. Allen, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Combination of low-dose cisplatin and gemcitabine for treatment of elderly patients with advanced non-small-cell lung cancer

J. Feliu, E. Casado, M. González-Barón, 2003, Cancer Chemotherapy and Pharmacology.

Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survival

S. Tomany, F. Cabanillas, A. Younes, 2001, Bone Marrow Transplantation.

Phase I and pharmacokinetic study of DACA (XR5000): a novel inhibitor of topoisomerase I and II

P. Beale, N. Bleehen, P. Vasey, 1999, British Journal of Cancer.

A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome.

P. Mclaughlin, R. Orlowski, C. Bueso-Ramos, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

A pilot study of high-dose interleukin-3 treatment of relapsed follicular small cleaved-cell lymphoma: hematologic, immunologic, and clinical results.

M. Andreeff, P. Mclaughlin, F. Cabanillas, 1996, Blood.

Pharmacokinetic food-effect study of abiraterone acetate (AA) in patients with metastatic castration resistant prostate cancer (mCRPC): The ABIFOOD trial (EudraCt number: 2012-003226-25).

L. Paz-Ares, I. Durán, M. Espinosa, 2016 .